{"id":215240,"link":"https://chinadigitaltimes.net/chinese/2012/03/印度政府下令仿制癌症治疗药物，价格削减97/","date":"2012-03-13T12:49:33Z","modified":"2012-03-13T12:49:33Z","title":"印度政府下令仿制癌症治疗药物，价格削减97%","content":"<p>印度政府作出了一项重要决定，授权国内制药公司仿制受专利保护的癌症治疗药物，使抗癌药物能让普通人负担得起。这一决定可能会创造一个先例。 印度专利局批准了Natco Pharma制药公司销售用于肾癌和肝癌治疗仿制药多吉美（Nexavar），一个月疗程120胶囊包售价8880印度卢比（约合175美元），而拜耳公司的售价为28万卢比（约合5500美元），价格能让大多数病人负担得起。Natco表示，它将会在每季度将6%净销售额作为专利费支付给拜耳公司。拜耳对印度的决定表示失望，称将考虑采取行动保护它的知识产权。<img width=\"1\" height=\"1\" src=\"http://solidot.org.feedsportal.com/c/33236/f/556826/s/1d637d7e/mf.gif\" border=\"0\" /></p>\n<div>\n<table border=\"0\">\n<tr>\n<td valign=\"middle\"><a href=\"http://share.feedsportal.com/viral/sendEmail.cfm?lang=en&#038;title=%E5%8D%B0%E5%BA%A6%E6%94%BF%E5%BA%9C%E4%B8%8B%E4%BB%A4%E4%BB%BF%E5%88%B6%E7%99%8C%E7%97%87%E6%B2%BB%E7%96%97%E8%8D%AF%E7%89%A9%EF%BC%8C%E4%BB%B7%E6%A0%BC%E5%89%8A%E5%87%8F97%25&#038;link=http%3A%2F%2Fscience.solidot.org%2Farticle.pl%3Fsid%3D12%2F03%2F13%2F1048214%26amp%3Bfrom%3Drss\"><img src=\"http://chinadigitaltimes.net/chinese/files/2012/03/260f6417emailthis2.gif.gif\" border=\"0\" /></a></td>\n<td valign=\"middle\"><a href=\"http://res.feedsportal.com/viral/bookmark.cfm?title=%E5%8D%B0%E5%BA%A6%E6%94%BF%E5%BA%9C%E4%B8%8B%E4%BB%A4%E4%BB%BF%E5%88%B6%E7%99%8C%E7%97%87%E6%B2%BB%E7%96%97%E8%8D%AF%E7%89%A9%EF%BC%8C%E4%BB%B7%E6%A0%BC%E5%89%8A%E5%87%8F97%25&#038;link=http%3A%2F%2Fscience.solidot.org%2Farticle.pl%3Fsid%3D12%2F03%2F13%2F1048214%26amp%3Bfrom%3Drss\"><img src=\"http://chinadigitaltimes.net/chinese/files/2012/03/044291a1bookmark.gif.gif\" border=\"0\" /></a></td>\n</tr>\n</table>\n</div>\n<p><a href=\"http://da.feedsportal.com/r/129200228498/u/49/f/556826/c/33236/s/1d637d7e/a2.htm\"><img src=\"http://da.feedsportal.com/r/129200228498/u/49/f/556826/c/33236/s/1d637d7e/a2.img\" border=\"0\" /></a><img src=\"http://da.feedsportal.com/r/129200228498/u/49/f/556826/c/33236/s/1d637d7e/a2t.img\" border=\"0\" /></p>\n<div>\n<a href=\"http://feeds.feedburner.com/~ff/solidot?a=ll57yS_1dks:EqWNUu5k65c:yIl2AUoC8zA\"><img src=\"http://feeds.feedburner.com/~ff/solidot?d=yIl2AUoC8zA\" border=\"0\" /></a> <a href=\"http://feeds.feedburner.com/~ff/solidot?a=ll57yS_1dks:EqWNUu5k65c:7Q72WNTAKBA\"><img src=\"http://feeds.feedburner.com/~ff/solidot?d=7Q72WNTAKBA\" border=\"0\" /></a>\n</div>\n</p>\n<p><img src=\"http://solidot.org.feedsportal.com/c/33236/f/556826/s/1d637d7e/mf.gif\" /></p>\n<p><small>本文由自动聚合程序取自网络，内容和观点不代表数字时代立场</small></p>\n<p><iframe src=\"https://docs.google.com/spreadsheet/embeddedform?hl=zh-CN&#038;formkey=dGRpN3FrVThuMFFsZHBZcmNGLW94dEE6MQ\" width=\"510\" height=\"326\" frameborder=\"0\" marginheight=\"0\" marginwidth=\"0\">Loading&#8230;</iframe></p>\n<form method=\"POST\" action=\"http://www.feedblitz.com/f/f.fbz?AddNewUserDirect\">\n定期获得翻墙信息？<a href=\"http://www.feedblitz.com/f/?Sub=735659\">请电邮订阅数字时代</a> <br /><input name=\"EMAIL\" maxlength=\"64\" type=\"text\" size=\"25\" value=\"\"><br />\n<input name=\"FEEDID\" type=\"hidden\" value=\"735659\"><br />\n<input name=\"PUBLISHER\" type=\"hidden\" value=\"7485568\"><br />\n<input type=\"submit\" value=\"订阅!\"><br />\n</form>\n","author":1002,"categories":[20534],"tags":[5908,13774,8641,8795]}